Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
Reference
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
The British Equine Veterinary Association (BEVA) has announced that it is reducing the cost of its CPD by 50% this year and making its webinars free to members.
David Mountford, Chief Executive of BEVA said: "Last year we were able to capitalise on some efficiencies in other areas of BEVA operations. We are delighted to be able to hand the resulting benefits directly back to our members across all our CPD programme during 2013."
The Association says its CPD covers a broad range of topics is aimed at busy vets who need to build CPD points, whether new graduates, equine or mixed practitioners. It takes the form of clinical workshops, regional meetings, nursing meetings, webinars and one, two and three day practical courses, held in the UK.
This year's courses include:
For more information, visit http://www.beva.org.uk/news-and-events/beva-courses or ring +44(0)1638 723555 or email info@beva.org.uk.
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."
Jonathon is an RCVS & EBVS European Specialist in Veterinary Diagnostic Imaging, with a particular interest in MRI of the distal limb and has published scientific work on this subject, among others.
With the increase in availability and accessibility to CT for horses, VetCT says this hot topic will be well received by equine vets at all levels of experience.
VetCT’s Equine Teleradiology Manager, Charlotte Graham, said: “We can guarantee a highly engaging talk with plenty of useful tips on case selection for each modality as well as some interesting discussions in the Q&A session.”
To register for the webinar on 18th April and receive links to recordings of this and previous webinars in the 2023 series, sign up here: https://vetct.zoom.us/webinar/register/WN_zkctYZYWRUmRVIFTxrvvsA
www.vet-ct.com
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
The recommendation follows the analysis of data collected as part of the company's Talk About Laminitis disease awareness initiative, which has seen more than 47,000 horses tested for PPID since it was launched in 20121.
The data revealed that, regardless of presenting clinical signs, a horse aged 15-20 is three times more likely to have PPID compared to a horse under 10, and this risk increases with age. For example, a horse of 20-25 is six times more likely to have PPID compared to a horse under 10 and a horse that is 25-30 is 10 times more likely to have PPID.
Boehringer says that despite the high prevalence of PPID in the older horse population, the clinical signs of the disease are insidious in onset and owners may simply associate them with the ageing process.
One study demonstrated that in a single population of horses over the age of 15 only 1.6% of owners reported signs of PPID2. However, when the same group of horses were examined by a veterinary surgeon, 21% were found to have signs of the disease.
Dr Jo Ireland, veterinary surgeon at the University of Liverpool, said: "It is often difficult for owners to spot the signs of PPID as they frequently associate them with the ageing process. However, PPID is now the fifth most commonly diagnosed disease in horses in the UK3.
"We are therefore encouraging veterinary surgeons to routinely test horses over 15 years of age or those that are displaying signs of PPID with an ACTH test."
The 'Talk About Laminitis' disease awareness initiative runs from June until the end of October and aims to raise awareness of the underlying hormonal causes of laminitis – PPID and Equine Metabolic Syndrome (EMS). As part of the scheme, the laboratory fees for the blood test which detects PPID (the basal ACTH test) are free.
Redwings’ head of veterinary and care, senior veterinary surgeon Nicky Jarvis, said: "Any initiative that decreases the incidence of laminitis developing in an older equine is invaluable. Laminitis is an extremely distressing condition for both the horse and the owner and the long-term consequences can be devastating. Knowing the underlying cause is a huge help in tackling the disease and we would encourage anyone to take advantage of this offer and get their veteran checked out."
For further information about 'Talk About Laminitis', visit www.talkaboutlaminitis.co.uk or contact your local Boehringer Ingelheim account manager.
References
The Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week issued a reprimand to a veterinary surgeon for reckless certification of an equine passport, having found her to have been "wholly indifferent" as to whether the horse had been vaccinated properly against equine influenza.
Eleri Wyn Jones graduated from the University of Liverpool and qualified as a veterinary surgeon in 2006, before joining The Veterinary Practice on Bala Road in Dolgellau, Gwynedd, where she was also an authorised Local Veterinary Inspector (LVI). The principal of that practice is Iwan Parry, who himself was the subject of a DC hearing involving false certification earlier this year, for which he received a one-month suspension from the Register.
The Committee heard how, in late 2007, as Ms Jones was leaving the practice to begin her rounds, she was asked by a non-veterinary colleague to certify in a horse passport that two vaccinations for equine influenza had been administered. The horse in question was being liveried by a regular client of the practice, to whom the practice regularly dispensed veterinary vaccines (although Ms Jones was unaware of this), but had been recently purchased by someone who was not a registered client.
In evidence, Ms Jones admitted the certification process took her only 30 seconds and that she did not obtain any further information about the certification, either from clinical or non-clinical colleagues; nor did she check any other documentation before signing the passport, but assumed the vaccinations had been administered by a veterinary colleague. The Committee had to decide whether Ms Jones had acted recklessly, and to do so, Ms Jones' Counsel suggested the Committee would need to be satisfied that she "did not care less" whether or not the vaccinations had been given by a veterinary surgeon before signing the passport.
In reaching its decision, the Committee took into account the fact Ms Jones, on her own evidence, was generally familiar with RCVS guidance on certification and, as an authorised Local Veterinary Inspector, had certification training. It stated: "Whilst we recognise that Ms Jones received little or no mentoring from Mr Parry, we are satisfied that she would have been aware of the importance of veterinary certification. She was also aware that Mr Parry had been suspended as an LVI, due to certification issues, which had affected her own authorisation."
In view of these facts, and that Ms Jones made no attempt to obtain verification from any other source despite knowing she had not performed the vaccinations herself, the Committee decided that Ms Jones had been "wholly indifferent" to proper vaccination procedures and was therefore guilty of disgraceful professional conduct for reckless certification.
In reaching its decision on sanction, the Committee wished to remind members that cases involving improper certification would ordinarily result in suspension or removal from the Register. "We strongly disapprove of the circumstances in which Ms Jones certified this horse.
Clients, and external bodies, are entitled to rely upon the integrity of the veterinary surgeon in not certifying that horses have been vaccinated unless they have carried out the vaccinations themselves or have obtained full and proper evidence that vaccination has been carried out by another veterinary surgeon," it said.
In mitigation, however, the Committee took into account Ms Jones' age and inexperience, her previously good record, her good character and the significant number of supporting references from colleagues and clients alike. It was also mindful that any sanction's main purpose was to protect animal welfare and maintain public confidence in the profession, rather than to punish.
Nigel Swayne, chairing the Committee, concluded: "This is not a case where undertakings for training or monitoring are required. This isolated incident was a fateful misjudgement on a single occasion. We consider that the sanction most proportionate to the nature and extent of the charge, the public interest and the interests of Ms Jones is a reprimand."
Novartis Animal Health Inc. has completed an agreement with Luitpold Pharmaceuticals, Inc. that grants marketing rights for Adequan® Equine to Novartis in all major equine markets outside the U.S. The first launch of Adequan® Equine by Novartis will take place in Canada in June.
Adequan® Equine is indicated for treating joint dysfunction and lameness in horses caused by injury or degenerative problems. It is available for intramuscular and intra-articular administration. Adequan® is also indicated for treating joint dysfunction and lameness caused by injury or degenerative problems in dogs.
Mickey McDermott from Novartis' Communications Dept told VetSurgeon that the timing of Adequan's arrival in the UK depends on how long it takes to complete the registration transfers, but that the company hopes it'll be before the end of the year.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
MSD Animal Health has announced the launch of KBHH Yard Master – a new preventative healthcare and biosecurity app - as part of its ongoing Keeping Britain’s Horses Healthy (KBHH) campaign.
MSD says KBHH Yard Master has been created to link vets and yards where the majority of horses in Britain are kept. It aims to play a key role in protecting the health and welfare of the herd and in safeguarding the yard’s reputation and business.
Peter Young, Equine Business Manager at MSD Animal Health said: "Good biosecurity is essential in building and maintaining the reputation of a yard which, in turn, impacts on owner satisfaction and retention. It remains, however, a poorly understood subject despite its importance. We’ve therefore invested in the creation of KBHH Yard Master to help vets, yard managers, their employees and horse owners focus on preventative health and biosecurity measures; making best practice seem more achievable and easier to implement.
He added: "We were also fortunate to have input from Professor Josh Slater, who has been heavily involved in developing the content, evaluation and grading system behind the app assessment."
KBHH Yard Master covers all aspects of biosecurity, including everyday husbandry practices, managing new arrivals, running isolation facilities, infection control and personnel movement. MSD says it will frame a dialogue with yard managers regarding preventative healthcare and biosecurity in situ and provide instant feedback on current practices and risk. Following the on-site assessment, a report can be sent to the yard manager with tailor-made recommendations and timings, detailing how they can improve their yard’s biosecurity performance.
Peter added: "Based on the data gathered through the KBHH campaign we know that approximately half of horses are vaccinated for ‘flu. This means that there will be horses on yards, visited by vets, that are not vaccinated. KBHH Yard Master will help identify those horses and allow the vet to recommend appropriate vaccination schedules."
MSD has produced a range of supporting KBHH Yard Master materials to promote understanding, participation and compliance amongst yard staff and owners, including posters and downloadable booklets which explain aspects such as disease prevention, infection control and outbreak control.
A certificate of excellence is also available to be awarded to those yards which, following assessment, have a low overall biosecurity risk.
For more information, contact your MSD Animal Health Equine Account Manager or call MSD on 01908 685685.
Strangvac has been in development for over 25 years and Dechra says it's the first and only intramuscular vaccine to help protect against strangles.
Strangvac contains recombinant proteins CCE, Eq85 and IdeE from Streptococcus equi and has DIVA (Differentiating Infected from Vaccinated Animals) capability.
The vaccine contains no live bacteria or bacterial DNA, so will not trigger positive culture or PCR tests.
In trials the new vaccine protected more than 94% of horses1.
Dechra says it reduces the clinical signs of strangles including a high temperature, coughing, inappetence, difficulty swallowing and changes in demeanour, while also reducing the number of lymph node abscesses.
Strangvac can be given to foals from five months of age and two injections should be given at a four-week interval.
Horses at high risk of Streptococcus equi infection, such as those in livery, should be revaccinated after two months.
Based on measured antibody titres, immunological memory was found in horses following repeated vaccination six months after primary vaccination.
Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, said: “Strangvac is a ground-breaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”
https://www.dechra.co.uk/equine/vaccines
It is hoped the findings, which were unveiled at the House of Commons yesterday, will enable the welfare priorities of the UK’s 800,000 horses to be addressed.
This is the first time welfare organisations, breeders, the equine industry and the veterinary profession have come together to agree on a strategy to best improve the welfare of horses in the UK.
The equine welfare study found the welfare needs of many horses are not currently being met and the report has highlighted four welfare priorities.
Dr Siobhan Mullan, Research Fellow in Animal Welfare Science, Ethics and Law at the University of Bristol and one of the report’s authors, said: "Bringing together the views of people associated with horses in England and Wales has provided an overview of horse welfare, from the day-to-day concerns of equine caregivers to identifying four priority challenges to equine welfare.
"This research has also identified how equine welfare can be improved, by addressing both the priority challenges, and a wider set of industry and horse-based needs."
Roly Owers, World Horse Welfare Chief Executive, added: "This research report provides a vital insight to the UK’s equine sector, mapping out the welfare landscape from a wide range of sector experts and stakeholders.
"In order for World Horse Welfare and others to most effectively address the welfare challenges facing UK equines, we need to better understand today’s welfare priorities and this research will provide a valuable guide to help in driving the focus of our educational initiatives and resources over the next few years.”
The priority welfare challenges and solutions outlined in the report are:
Unresolved stress/pain behaviourProblems associated with unresolved stress/pain behaviour affect large numbers of horses, often for long durations with variable severity of suffering caused to individual horses.
More academic research is needed to fully understand the links between behaviour, stress and pain, and objective measures of stress and pain in horses should be developed. Vets, riding instructors, the Pony Club, riding clubs and the equine press have a role in educating horse caregivers about signs of stress and pain and the appropriate responses. Academics and experts also have a role in tackling this issue through evaluating the effectiveness of intervention programmes.
Inappropriate nutritionOverfeeding and obesity are the main welfare problems associated with nutrition and affect large numbers of horses, often for a long time with varying severity of suffering.
Vets have a key role in tackling the problems associated with inappropriate nutrition. A consistent approach by all vets is needed, to prevent horse owners choosing vets that don’t challenge owners about their horses’ nutrition. Feed companies can also play an important role in tackling this issue, although many feed companies already offer appropriate nutrition for a range of horses and exercise situations. Better owner education, based on existing good research, would ensure the right nutritional choices are made for individual horses.
Inappropriate stabling /turnoutWelfare of horses is compromised when the amount of time spent at pasture/stabled does not meet their individual needs, when they are kept in social isolation or when they are exposed to unsuitable grazing conditions. Welfare problems associated with incorrect stabling/turnout affect large numbers of horses for a long time with variable levels of suffering.
Although all horse owners make choices relating to the amount and type of stabling and turnout experienced by their horses, livery yard owners could play a role in addressing this issue. For example, by encouraging different approaches to management, including group housing and the use of all-weather turnout facilities. Strengthening legislation is another possible way for improvement but a ‘one size fits all’ approach would be inappropriate. For example, for some horses, turn out to pasture may not always be suitable.
Delayed deathHorses may be kept alive inappropriately resulting in firstly, prolonging welfare problems, such as continued suffering of a horse in pain. This affects relatively large numbers of horses, for short periods of time with the severity of suffering often being severe. Secondly, an increased risk of suffering, for example where horses are unwanted by their owners, become low value and subsequently aren’t cared for well.
One way for improvement could be by putting pressure on the EU to make changes to the passport regulations. In particular, legislation changes that would enable horses who had received medications, including Phenylbutazone, to be slaughtered to enter the human food chain after a six month withdrawal period. In addition, challenging negative attitudes of horse owners towards timely euthanasia is important.
The research, undertaken over a four year period, was to understand the welfare status of horses in England and Wales, identify priority welfare issues and explore horse owner and industry experts’ perceptions of these issues.
Stakeholders from across the equine industry contributed to the research: from vets to farriers and welfare charities to governing body representatives, participants represented a wide-reaching cross section of horse care roles and responsibilities.
The new pass offers both physical and virtual tickets so that the practice rota doesn't have to stop any member of the team from attending.
BEVA says the new tickets also offer a saving of up to £113 per vet.
David Mountford, Chief Executive of BEVA said: “We know that not every vet at a practice can attend congress every year because someone is always going to have to stay behind and work.
"So, by offering a mix of physical and virtual tickets in the pass it means those staying at home to look after the practice can still benefit from the live stream as well as the six-month access to all the lectures afterwards.
"Congress always contains plenty of relevant and dedicated content for nurses, so the pass obviously includes nurse tickets too.”
Practice Passes are available for BEVA members in three packages: small (£599), medium (£1,333) and large (£2,666).
Individual early bird BEVA member prices are £499 for vets and £187 for vet nurses for all three days (with concessions available for those in their first three years’ post-graduation or on a lower salary).
Practice Passes and early bird tickets are available to purchase until Monday 1 August 2022.
Day tickets are also available.
Virtual tickets are £199 for vets and £40 for nurses.
For more information, or to book tickets, visit http://www.bevacongress.org
The webinars each last between three and five minutes and are part of the 2016 ‘Talk About Laminitis’ disease awareness initiative to help detect, manage and monitor PPID.
The webinars can be viewed on the Boehringer Academy website – www.boehringer-academy.co.uk - and podcast versions are also available enabling veterinary professionals to listen to them ‘on the go’.
The first series includes:
The second webinar series covers:
For further information on the webinars or podcasts visit www.boehringer-academy.co.uk or contact your local Boehringer Ingelheim territory manager.
Kruuse UK has announced that it will be launching its new Android telemetric ECG system at BEVA 2011.
The original Televet 100 supports transmission of ECG data to a range of approx 100m (330ft), allowing recording and displaying of real time data only within a confined lunging or riding arena. By linking this system to a mobile network via 3G Android phone and a Windows 7 based tablet PC, the new Televet system overcomes this range limitation.
The new system requires the rider/horse to carry a 3G mobile phone which transmits data over the mobile internet, allowing the veterinary surgeon to display and record real time data on any PC/laptop with internet access or mobile internet connection. This also includes GPS information collected by the phone allowing the ECG, heart rate and velocity of the horse to be displayed in parallel.
The Android Telemetric ECG system is specifically targeted towards veterinary applications in the field of sports horses where extended range is particularly useful, such as endurance riding, three day eventing and racing.
Televet software can now also be integrated in Dicom infrastructures in practice for data capture and recording.
Sarah Stokes, Kruuse Equine Territory Manager said: "the flexibility and simplicity of the system along with immediate access to ECG data of patients will be an invaluable diagnostic tool for UK vets allowing vital support for patients and owners wherever they are."
Visitors to the Kruuse stand at BEVA 2011 will also have the chance to win an Acer ICONI W500 tablet worth £500.
The new tool is part of a package that also includes posters and SMS texts to support veterinary practices in raising awareness of gastric ulcers to horse owners.
Equine Gastric Ulcer Syndrome (EGUS) is a serious and common condition and any type of horse can be at risk.1 EGUS can have a profound impact on a horse’s condition and performance and can be life threatening in foals. It is a challenging condition to diagnose as the clinical signs are often vague and not always present.1
Gastroscopy is the only method currently available for a definitive diagnosis. Of the two types of disease equine squamous gastric disease is graded on a numeric scale with 1 being the least severe and 4 being the most serious. Equine glandular gastric disease can be very varied in terms of location and type so grading this disease on a score system is no longer recommended. Instead it is now usually described in terms of location, severity and appearance.2
The new tool has been designed to help vets to map the area affected by gastric disease and record the details in an accessible format. This information, together with treatment and management recommendations, can be shared easily with the client. Posters explaining gastric ulceration have been designed to help increase awareness and understanding of EGUS amongst horse owners.
Zoetis says effective treatment usually involves a combination of management and medical treatments. UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.3 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.3,4 One syringe contains enough UlcerGold for a daily dose for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
A research project funded by equine charity The Horse Trust has found that lameness is the most common reason for euthanasing a geriatric horse.
According to the charity, this research is the first in the UK to provide data on the causes of death in geriatric horses. Although post-mortem studies have provided some data regarding causes of death, "old age" was previously reported as a common reason for the euthanasia of adult horses.
The research was carried out by Joanne Ireland at the University of Liverpool and led by Dr Gina Pinchbeck. Ireland surveyed horse owners living in the North-West and Midlands areas of England and North Wales who have a horse aged 15 years or older. 918 owners of geriatric horses were followed in a cohort study and 118 mortalities were reported during the 18 month follow-up period, of which 111 were euthanased.
The researchers found that 24% of horses were euthanased due to lameness; an additional 12% were euthanased due to laminitis - a common cause of lameness. After lameness, colic was the next most common cause of euthanasia, with 21% of owners citing this as the main reason.
In an earlier stage of the project, the researchers had found that half the geriatric horses surveyed suffered from lameness, but only 24% of owners reported the problem.
Dr Pinchbeck said: "Although lameness is common in older horses, this is the first study to quantify its contribution to their mortality.
"Owners are often missing the early signs of lameness in their horse, which means the condition isn't being managed and may deteriorate faster."
Dr Pinchbeck said it would be useful to carry out further research into lameness in geriatric horses to find out the main causes of lameness and how these may be prevented or treated.
The research team also found that half of the horses euthanased were suffering from concurrent health problems and these influenced the owner's decision to euthanase in 43% of cases. The most frequently reported additional health problems were musculoskeletal problems, such as arthritis.
The mortality rate among the horses surveyed was 11 per 100 horse-years at risk, meaning that if 100 geriatric horses were followed for a year, an average of 11 would die. The mortality rate for horses over 30 years of age was over five times the rate than in horses aged 15 - 19 years.
Jeanette Allen, Chief Executive of The Horse Trust, said the data provided by this research is likely to provide useful information for both horse owners and vets to enable them to improve the welfare of older horses. She said: "As there are a significant number of geriatric horses in the UK, it is vital that we understand more about the health problems that affect them. We hope that more owners of older horses will give their horse an annual health-check to enable the horse to have a longer, healthier life."
The research was published in the September 2011 issue of Preventive Veterinary Medicine.
Merial has launched Equioxx, a new pain management product which the company says is the first COX-2 specific NSAID for horses
Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Merial says Equioxx is the only NSAID that is highly COX-2 selective (up to 643 times more selective for COX-2 than COX-1), acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels.
Equioxx contains the active ingredient firocoxib, and Merial says it is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Equioxx is available as either a low dose injectable solution or a palatable oral paste.
For more information contact Merial Customer Services on 0870 6000 123
The RCVS Charitable Trust has made two 'Blue Sky' grants of £20,000 each for research into feline rotavirus and equine gut bacteria.
One award has been made to Allison German and Kenton Morgan at the University of Liverpool as a Richard Daubney Research Fellowship. This will enable research to be undertaken into the molecular epidemiology and zoonotic potential of feline rotavirus in UK cats.
Allison said: "Feline rotaviruses have been identified in diarrhoeic children in Japan, Italy, Israel and America, but because of limited funding options, there has been no systematic study of rotaviruses in cats, so the prevalence, risk factors and zoonotic potential are unknown. I am pleased that the Trust has recognised the importance of emerging infectious diseases in companion animals and their potential role in animal and human health."
By assessing faecal samples from cats within Cats Protection Adoption Centres in the UK, the study aims to discover the prevalence of rotavirus in this cat population and broadly identify the strains of feline rotavirus that are circulating, including looking for any with identity to human strains. The study will also determine whether the molecular epidemiology of rotavirus in the cat population enables understanding of the diversification and evolution of rotaviruses in people.
A second Blue Sky award of £20,000 has been made to Chris Proudman and Alistair Darby, also at the University of Liverpool, to research the role of gut bacteria in horse health and disease. Called Metagenomic Analytical Utilities for Equines (MANURE), the project will sequence DNA from microbes taken from horse intestines, and analyse the diversity, composition and abundance of the microbial populations. This is expected to improve veterinary understanding of the role of equine gut bacteria, and benefit horses and their owners. Tools being developed to characterise and investigate equine gut microbiota, and findings expected, such as the discovery of novel bacteria, should also be useful to other research.
RCVS Trust Director Cherry Bushell said: "As usual, the standard of applications was very good, although we do continue to receive a relatively high number of applications for projects that the assessors judge to be more 'surveys' than genuine blue sky research.
"In deciding which research to fund, a number of factors are taken into account, such as the quality and strength of the research team, the likelihood of success, and whether a genuine gap in knowledge has been identified. For example, the feline rotavirus research could have important findings in the longer term if it is found that there is genuine risk to human health, and also shows clear potential for further study. Similarly, the equine gut bacteria study is likely to increase considerably knowledge over the longer term and to attract funding from elsewhere for further research."